FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Fund ProfileState Street SPDR S&P Biotech ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
XBI
State Street SPDR S&P Biotech ETF ETF AnalysisComprehensive ETF analysis for State Street SPDR S&P Biotech ETF (XBI) including NAV, expense ratio, dividend yield, sector breakdown, and holdings data.ETF AnalysisXBI
XBI
State Street SPDR S&P Biotech ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
XBI
  1. Home
  2. Screener
  3. State Street SPDR S&P Biotech ETFXBIETF
State Street SPDR S&P Biotech ETF Logo

State Street SPDR S&P Biotech ETF

ETF
🇺🇸XBI•AMEX•Equity

Your view on XBI

State Street SPDR S&P Biotech ETF Logo

State Street SPDR S&P Biotech ETF

ETFSPDR
🇺🇸XBI•AMEX•Equity
AUM (USD)$10.03B
Expense Ratio0.35%
Yield (TTM)0.38%
Holdings165

Sentiment

—

AUM (USD)

$10.03B

Expense Ratio

0.35%

Yield (TTM)

0.38%

Holdings

165

Sentiment

—
Fund Overview

Overview

What the fund invests in, who runs it, and what it costs.

State Street SPDR S&P Biotech ETF (XBI) is an Equity fund from SPDR, listed since 2006, with $10.0B in assets under management, a 0.35% expense ratio and a NAV of $148.54 USD.

Overview for State Street SPDR S&P Biotech ETF

Fund Type
ETF
Fund Issuer
SPDR
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
January 31, 2006
Domicile
US
Website
ssga.com/us/en/institutional/etfs/state-street-spdr-sp-biotech-etf-xbi
Fund Type
ETF
Fund Issuer
SPDR
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
January 31, 2006
Domicile
US
Website
ssga.com/us/en/institutional/etfs/state-street-spdr-sp-biotech-etf-xbi
Fund Type
ETF
Fund Issuer
SPDR
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
January 31, 2006
Domicile
US
Website
ssga.com/us/en/institutional/etfs/state-street-spdr-sp-biotech-etf-xbi

About this fund

The State Street SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the "Index")Seeks to provide exposure to the Biotechnology segment of the…

Fund Data

Price Chart

Market price history and trading volume.

Key Facts

Cost, yield, size, and the fund's reference data.

Equity

Expense Ratio

0.35%

Yield (TTM)

0.38%

AUM

$10.03B

Fund Details

NAV$148.54 USD
Holdings165
Average Volume8.93M
Inception DateJanuary 31, 2006
Asset ClassEquity
Fund IssuerSPDR
DomicileUS
ISINUS78464A8707
CUSIP78464A870
NAV CurrencyUSD

Expense Ratio

0.35%

Dividend Yield (TTM)

0.38%

Assets Under Management

$10.03B

NAV

$148.54 USD

Holdings

165

Average Volume

8.93M

Inception Date

January 31, 2006

Asset Class

Equity

Fund Issuer

SPDR

Domicile

US

ISIN

US78464A8707

CUSIP

78464A870

NAV Currency

USD

Expense Ratio

0.35%

Dividend Yield (TTM)

0.38%

Assets Under Management

$10.03B

NAV

$148.54 USD

Holdings

165

Average Volume

8.93M

Inception Date

January 31, 2006

Asset Class

Equity

Fund Issuer

SPDR

Domicile

US

ISIN

US78464A8707

CUSIP

78464A870

NAV Currency

USD

Distributions · last 12 months

Semi-Annual · 2 payments

Ex-datePaidAmount
Jun 22, 2026Jun 24, 2026$0.1381
Dec 22, 2025Dec 24, 2025$0.4066
Total, 12 months$0.54 a share

Dividend yield (TTM) 0.38% = $0.54 paid per share in the 12 months to Nov 20, 2026 ÷ the $145.04 price. Past distributions; future payments can differ.

Data last updated: Nov 9, 2026, 08:10 AM

Sectors

How the fund's assets are split across sectors.

2 sectors
  • 1Healthcare
    99.5%
  • 2Financial Services
    0.5%

Top sector

Healthcare

Top weight

99.5%

Top 3 weight

100.0%

Holdings

The securities the fund owns, by weight.

167 positions
1MRNAMODERNA INC
2.26%
2TGTXTG THERAPEUTICS INC
1.89%
3BIIBBIOGEN INC
1.86%
4EXELEXELIXIS INC
1.83%
5REGNREGENERON PHARMACEUTICALS
1.83%
6SYRESPYRE THERAPEUTICS INC
1.82%
7GILDGILEAD SCIENCES INC
1.81%
8ABBVABBVIE INC
1.78%
9UTHRUNITED THERAPEUTICS CORP
1.78%
10AMGNAMGEN INC
1.77%
11NBIXNEUROCRINE BIOSCIENCES INC
1.64%
12ORKAORUKA THERAPEUTICS INC
1.63%
13ALKSALKERMES PLC
1.61%
14VRTXVERTEX PHARMACEUTICALS INC
1.61%
15BBIOBRIDGEBIO PHARMA INC
1.60%

Concentration

Total Holdings167
Top 10 Weight18.62%
Top HoldingMRNA
Top Weight2.26%
1MRNAMODERNA INC
2.26%
2TGTXTG THERAPEUTICS INC
1.89%
3BIIBBIOGEN INC
1.86%
4EXELEXELIXIS INC
1.83%
5REGNREGENERON PHARMACEUTICALS
1.83%
6SYRESPYRE THERAPEUTICS INC
1.82%
7GILDGILEAD SCIENCES INC
1.81%
8ABBVABBVIE INC
1.78%
9UTHRUNITED THERAPEUTICS CORP
1.78%
10AMGNAMGEN INC
1.77%
11NBIXNEUROCRINE BIOSCIENCES INC
1.64%
12ORKAORUKA THERAPEUTICS INC
1.63%
13ALKSALKERMES PLC
1.61%
14VRTXVERTEX PHARMACEUTICALS INC
1.61%
15BBIOBRIDGEBIO PHARMA INC
1.60%

Total Holdings

167

Top 10 Weight

18.62%

Top Holding

MRNA

Top Weight

2.26%

1MRNAMODERNA INC
2.26%$220.69M
2TGTXTG THERAPEUTICS INC
1.89%$184.27M
3BIIBBIOGEN INC
1.86%$181.40M
4EXELEXELIXIS INC
1.83%$178.30M
5REGNREGENERON PHARMACEUTICALS
1.83%$178.29M
6SYRESPYRE THERAPEUTICS INC
1.82%$177.75M
7GILDGILEAD SCIENCES INC
1.81%$176.70M
8ABBVABBVIE INC
1.78%$173.32M
9UTHRUNITED THERAPEUTICS CORP
1.78%$173.21M
10AMGNAMGEN INC
1.77%$172.49M
11NBIXNEUROCRINE BIOSCIENCES INC
1.64%$159.88M
12ORKAORUKA THERAPEUTICS INC
1.63%$159.36M
13ALKSALKERMES PLC
1.61%$157.16M
14VRTXVERTEX PHARMACEUTICALS INC
1.61%$156.79M
15BBIOBRIDGEBIO PHARMA INC
1.60%$156.16M

Total Holdings

167

Top 10 Weight

18.62%

Top Holding

MRNA

Top Weight

2.26%

Peer Comparison

Comparables

Funds similar to this one.

Side by side on what an ETF is compared on20 funds
FundAsset classExpense ratioAssetsHoldings
XBIState Street SPDR S&P Biotech ETFThis fundEquity0.35%$10.0B165

Comparable funds

  • AIQGlobal X - Artificial Intelligence & Technology ETFEquity0.68%$9.1B88
  • BBINJPMorgan BetaBuilders International Equity ETFInternational Equity0.07%$6.6B629
  • BBUSJPMorgan BetaBuilders U.S. Equity ETFUS Equity0.02%$9.8B469
  • EWZiShares MSCI Brazil ETFEquity0.59%$9.1B45
  • FDLFirst Trust Morningstar Dividend Leaders Index FundEquity Income0.43%$8.4B100
  • IDViShares International Select Dividend ETFEquity0.50%$8.4B100
  • KBWBInvesco KBW Bank ETFEquity0.35%$6.5B26
  • TCAFT. Rowe Price Capital Appreciation Equity ETFEquity0.31%$7.9B96

More SPDR ETFs

  • ONEVState Street SPDR Russell 1000 Low Volatility Focus ETFEquity0.20%$293M446
  • ONEYState Street SPDR Russell 1000 Yield Focus ETFEquity0.20%$669M296
  • OZF.AXState Street SPDR S&P/ASX 200 Financials EX A-REIT ETFEquity0.34%$43M30
  • OZR.AXState Street SPDR S&P/ASX 200 Resources ETFEquity0.34%$284M60
  • PCHXState Street SPDR Nasdaq MyPaycheck ETFMulti-Asset0.35%$3M10
  • PRABState Street IG Public & Private ABS ETFFixed Income0.39%$28M79
  • PRIVSPDR SSGA IG Public & Private Credit ETFFixed Income0.55%$805M358
  • PRSDState Street Short Duration IG Public & Private Credit ETFFixed Income0.45%$115M164
  • PSKState Street SPDR ICE Preferred Securities ETFEquity0.45%$619M165
  • QEFAState Street SPDR MSCI EAFE StrategicFactors ETFEquity0.30%$1.0B624
  • QEMMState Street SPDR MSCI Emerging Markets StrategicFactors ETFEquity0.30%$55M788
  • QMIX.AXState Street SPDR MSCI World Quality Mix ETFEquity0.18%$484M1,121
Ownership & News

Fund Holders

Institutions that own shares of this fund.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for this company. Press releases and market coverage, newest first.

News

Latest Market News

News

Latest Market News